Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC)

// Dominique Farge 1 , Francis Cajfinger 2 , Nicolas Falvo 3 , Toufek Berremili 4 , Francis Couturaud 5 , Okba Bensaoula 6 , Lionel Vedrine 7 , Hocine Bensalha 1 , Isabelle Bonnet 8 , Denis Pere-Verge 9 , Marie Coudurier 10 , Veronique Li 11 , Hanadi Rafii 1 , Ilham Benzidia 1 , Jean M. Connors 12, * and Matthieu Resche-Rigon 13, * 1 Assistance Publique-Hopitaux de Paris, Saint-Louis Hospital, Internal Medicine, Autoimmune and Vascular Disease Unit, UF 04, Diderot University, Paris, France 2 Medical Oncology, Hopital Pitie-Salpetriere, Paris, France 3 Departement de Pathologie Vasculaire, CHU Dijon, Dijon Cedex, France 4 Department of Cardiology, Annecy Hospital, Annecy, France 5 Brest University Hospital, CHU de Brest, Brest, France 6 Department of Oncology, CLCC Curie Institute, Centre Rene Huguenin, Saint Cloud, France 7 Hopital d'Instruction des Armees du Val-de-Grâce, Paris, France 8 Department of Oncology, Hospital of Valenciennes, Valenciennes, France 9 CH Saint Joseph Saint Luc, Lyon, France 10 Chambery CH, Chambery, France 11 CH Thonon-Les-Bains, Thonon-les-Bains, France 12 Hematology Division, Harvard Medical School, Boston, MA, USA 13 Service de Biostatistique et Information Medicale, AP-HP Hopital Saint-Louis, Paris, France * These authors contributed equally to this work Correspondence to: Dominique Farge, email: dominique.farge-bancel@aphp.fr Keywords: cancer thrombosis; venous thromboembolism; anticoagulation therapy; quality of life; LMWH Received: March 30, 2018 Accepted: May 02, 2018 Published: June 05, 2018 ABSTRACT Background: Clinical guidelines recommend at least 3-months low molecular weight heparin (LMWH) treatment for established venous thromboembolism (VTE) in cancer patients. However, no study has analyzed the impact of 3–6 months of LMWH therapy on quality-of-life (QoL) in cancer patients. Results: Among 400 cancer patients included at M0, 88.8% received long-term LMWH. Using a random-effects linear regression model with time as covariate, QoL scores in the MOS SF-36 (Global HRQoL, 1.3-fold per month [95% confidence interval (CI) 0.81–1.79], p < 0.0001) and EORTC QLQ-C30 (global health status/qol, 2.25-fold per month [95% CI 1.63–2.88]; p < 0.0001) questionnaires significantly improved over the 6-month study period in patients treated with LMWH, while VEINES-QOL scores did not change. In the MOS SF-36 and EORTC QLQ-C30, the following factors were associated with change in QoL: symptomatic VTE, cancer dissemination and histological type. Factors pertaining to reduced mobility were also identified as significant predictors of QoL outcomes, including being bedridden in the MOS SF-36 and ECOG score ≥ 2 in the EORTC QLQ-C30. Presence of acute infection and not undergoing anti-angiogenic therapy were additional factors associated with QoL improvement in the EORTC QLQ-C30. Methods: QUAVITEC, a prospective, longitudinal, multicenter study, recruited all consecutive eligible adult cancer patients with objectively confirmed VTE between February 2011 and 2012. Patients were asked to answer three QoL questionnaires at anticoagulant treatment initiation (M0) and at 3 (M3) and 6 (M6)-month follow-ups. Conclusion: QUAVITEC is the first study to show that QoL was improved in cancer patients receiving long-term LMWH treatment for established VTE.